Erin Hofstatter, MD

• Andrea Silber
• Anees Chagpar
• Cary Gross
• Christos Hatzis
• Daniel Zelterman
• David Rimm
• Donald Lannin
• Eric Winer
• Hongyu Zhao
• Ian Krop
• Jenerius Aminawung
• Jill Lacy
• Kerin Adelson
• Lajos Pusztai
• Liva Andrejeva-Wright
• Malini Harigopal
• Marcella Nunez-Smith
• Mariya Rozenblit
• Melinda Irwin
• Michael DiGiovanna
• Michal Marczyk
• Neal Fischbach
• Patricia LoRusso
• Peter Gershkovich
• Stacey Stein
• Suzanne B. Evans

Breast Neoplasms

• Financial toxicity in patients with advanced solid malignancies participating in early-phase clinical trials.Blanter J, Werner M, Kier M, Hapanowicz O, Itani M, Ahmad M, DeMerchant M, Eder J, Galsky M, Hammad A, King P, Lachowicz M, Lucas N, Marron T, Shelton G, Wu K, Xu S, LoRusso P, Hofstatter E, Doroshow D. Financial toxicity in patients with advanced solid malignancies participating in early-phase clinical trials. Journal Of Clinical Oncology 2022, 40: 267-267. DOI: 10.1200/jco.2022.40.28_suppl.267.
• Ovarian cancer risk-reduction and screening in BRCA 1/2 mutation carriers (383)DiSilvestro J, Dexter J, Haddad J, Beffa L, Raker C, Laprise J, Wilbur J, Clark M, Bradford L, Brown A, Hofstatter E, Dalela D, Toland M, Robison K, Stuckey A. Ovarian cancer risk-reduction and screening in BRCA 1/2 mutation carriers (383). Gynecologic Oncology 2022, 166: s195-s196. DOI: 10.1016/s0090-8258(22)01605-5.
• Abstract P5-13-21: Relationship between circulating tumor DNA and response to neoadjuvant niraparib in HER2-negative, BRCA-mutated breast cancerShan M, Spring L, Liu M, Hamilton E, Irie H, Santa-Maria C, Isakoff S, Reeves J, Ellisen L, Lim L, Garg K, Bertucci C, Feng B, Zhang H, Sun K, Graham J, Hofstatter E, Han H. Abstract P5-13-21: Relationship between circulating tumor DNA and response to neoadjuvant niraparib in HER2-negative, BRCA-mutated breast cancer. Cancer Research 2022, 82: p5-13-21-p5-13-21. DOI: 10.1158/1538-7445.sabcs21-p5-13-21.
• Abstract P3-07-01: Young women with breast cancer and high risk family history but no high penetrance germline mutations have a higher load of rare high functional impact germline variants in cancer relevant genesRozenblit M, Qing T, Ye Y, Zhao H, Hofstatter E, Singh V, Reisenbichler E, Murray M, Pusztai L. Abstract P3-07-01: Young women with breast cancer and high risk family history but no high penetrance germline mutations have a higher load of rare high functional impact germline variants in cancer relevant genes. Cancer Research 2022, 82: p3-07-01-p3-07-01. DOI: 10.1158/1538-7445.sabcs21-p3-07-01.
• Abstract OT2-24-02: ZEST: Randomized phase III study evaluating efficacy and safety of niraparib in patients with HER2-negative BRCA-mutated or triple-negative breast cancer with detectable circulating tumor DNA after definitive therapyTurner N, Cescon D, Loibl S, Janni W, Rugo H, Balmaña J, Crowley C, Chung J, Fucli G, Hofstatter E, Frenkl T, Telli M. Abstract OT2-24-02: ZEST: Randomized phase III study evaluating efficacy and safety of niraparib in patients with HER2-negative BRCA-mutated or triple-negative breast cancer with detectable circulating tumor DNA after definitive therapy. Cancer Research 2022, 82: ot2-24-02-ot2-24-02. DOI: 10.1158/1538-7445.sabcs21-ot2-24-02.
• The Effect of Black Cohosh on Ki67 expression and Tumor Volume: A Pilot Study of Ductal Carcinoma in Situ PatientsTrant A, Chagpar A, Wei W, Neumeister V, Rimm D, Stavris K, Lurie B, Frederick C, Andrejeva L, Raghu M, Killelea B, Horowitz N, Lannin D, Knill-Selby E, Sturrock T, Hofstatter E. The Effect of Black Cohosh on Ki67 expression and Tumor Volume: A Pilot Study of Ductal Carcinoma in Situ Patients. Integrative Cancer Therapies 2022, 21: 15347354221137290. PMID: 36444764, PMCID: PMC9716631, DOI: 10.1177/15347354221137290.
• Twenty-one-gene recurrence score (RS) in germline (g)CHEK2 mutation-associated versus sporadic breast cancers (BC): A multi-site case-control study.Afghahi A, Marsh S, Winchester A, Gao D, Parris H, Axell L, Ellisen L, Hofstatter E, Kurian A, Wood M, Zakalik D, Mullin C, Caswell-Jin J, Borges V, Tung N. Twenty-one-gene recurrence score (RS) in germline (g)CHEK2 mutation-associated versus sporadic breast cancers (BC): A multi-site case-control study. Journal Of Clinical Oncology 2021, 39: 10531-10531. DOI: 10.1200/jco.2021.39.15_suppl.10531.
• Barriers to hormone replacement therapy following prophylactic bilateral salpingo-oophorectomy in BRCA1/2 mutation carriersDiSilvestro J, Haddad J, Robison K, Beffa L, Laprise J, Wilbur J, Raker C, Hofstatter E, Dalela D, Brown A, Bradford L, Toland M, Stuckey A. Barriers to hormone replacement therapy following prophylactic bilateral salpingo-oophorectomy in BRCA1/2 mutation carriers. Gynecologic Oncology 2020, 159: 260. DOI: 10.1016/j.ygyno.2020.05.448.
• Reproductive decision making and partnering in BRCA1/2 mutation carriersDiSilvestro J, Haddad J, Robison K, Beffa L, Laprise J, Wilbur J, Raker C, Hofstatter E, Dalela D, Brown A, Bradford L, Toland M, Stuckey A. Reproductive decision making and partnering in BRCA1/2 mutation carriers. Gynecologic Oncology 2020, 159: 260-261. DOI: 10.1016/j.ygyno.2020.05.449.
• Abstract P2-09-02: Evidence of accelerated epigenetic aging of breast tissues in patients with breast cancer compared to women without cancerHofstatter E, Levine M, Liu Z, O'Meara T, Dalela D, Pusztai L. Abstract P2-09-02: Evidence of accelerated epigenetic aging of breast tissues in patients with breast cancer compared to women without cancer. Cancer Research 2020, 80: p2-09-02-p2-09-02. DOI: 10.1158/1538-7445.sabcs19-p2-09-02.
• Abstract P5-13-02: Neoadjuvant aromatase inhibitor therapy plus the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 negative breast cancer and an oncotype Dx recurrence score (≤25)Abu-Khalaf M, Aderhold K, Marczyk M, Chung G, Hofstatter E, Sanft T, Silber A, DiGiovanna M, Zelterman D, Puzstai L, Hatzis C. Abstract P5-13-02: Neoadjuvant aromatase inhibitor therapy plus the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 negative breast cancer and an oncotype Dx recurrence score (≤25). Cancer Research 2020, 80: p5-13-02-p5-13-02. DOI: 10.1158/1538-7445.sabcs19-p5-13-02.
• Abstract GS6-03: Cisplatin versus doxorubicin/cyclophosphamide as neoadjuvant treatment in germline BRCA mutation carriers ( BRCA carriers) with HER2-negative breast cancer: Results from the INFORM trial (TBCRC 031)Tung N, Arun B, Hofstatter E, Hacker M, Toppmeyer D, Isakoff S, Borges V, Legare R, Isaacs C, Wolff A, Marcom P, Mayer E, Lange P, Goss A, Krop I, Winer E, Schnitt S, Garber J. Abstract GS6-03: Cisplatin versus doxorubicin/cyclophosphamide as neoadjuvant treatment in germline BRCA mutation carriers ( BRCA carriers) with HER2-negative breast cancer: Results from the INFORM trial (TBCRC 031). Cancer Research 2020, 80: gs6-03-gs6-03. DOI: 10.1158/1538-7445.sabcs19-gs6-03.
• Investigation of HBOC germline mutations in women diagnosed with breast cancer in Trinidad and Tobago.Parkinson G, Chagpar A, Alleyne-Mike K, Nunez-Smith M, Zhou A, Servais L, Hofstatter E. Investigation of HBOC germline mutations in women diagnosed with breast cancer in Trinidad and Tobago. Journal Of Clinical Oncology 2019, 37: 6574-6574. DOI: 10.1200/jco.2019.37.15_suppl.6574.
• Abstract P3-05-01: Age-related methylation signals of breast cancer risk in bloodHofstatter E, Levine M, Hatzis C, Pusztai L. Abstract P3-05-01: Age-related methylation signals of breast cancer risk in blood. Cancer Research 2019, 79: p3-05-01-p3-05-01. DOI: 10.1158/1538-7445.sabcs18-p3-05-01.
• The effect of black cohosh on Ki67 levels in DCIS patients.Hofstatter E, Trant A, Stavris K, Horowitz N, Killelea B, Lannin D, Neumeister V, Rimm D, Chagpar A. The effect of black cohosh on Ki67 levels in DCIS patients. Journal Of Clinical Oncology 2018, 36: e13541-e13541. DOI: 10.1200/jco.2018.36.15_suppl.e13541.
• Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC).Pusztai L, Hofstatter E, Chung G, Horowitz N, Lannin D, Killelea B, Chagpar A, DiGiovanna M, Frederick C, Burello T, Harigopal M. Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC). Journal Of Clinical Oncology 2018, 36: 586-586. DOI: 10.1200/jco.2018.36.15_suppl.586.
• Breast cancer risk perception and adherence to u.s. cancer prevention guidelines.Eckroate J, Chagpar A, Hofstatter E. Breast cancer risk perception and adherence to u.s. cancer prevention guidelines. Journal Of Clinical Oncology 2018, 36: 1554-1554. DOI: 10.1200/jco.2018.36.15_suppl.1554.
• Abstract P2-04-02: Comparison of DNA methylation patterns in normal breast tissue from women with and without breast cancerHofstatter E, Zhu Y, Horvath S, Chagpar A, Wali V, Bossuyt V, Storniolo A, Hatzis C, Patwardhan G, Von Wahlde M, Butler M, Epstein L, Stavris K, Sturrock T, Au A, Kwei S, Pusztai L. Abstract P2-04-02: Comparison of DNA methylation patterns in normal breast tissue from women with and without breast cancer. Cancer Research 2018, 78: p2-04-02-p2-04-02. DOI: 10.1158/1538-7445.sabcs17-p2-04-02.
• Abstract PD6-02: Immunological differences between primary and metastatic breast cancerSzekely B, Bossuyt V, Li X, Baine M, Silber A, Sanft T, Hofstatter E, Mougalian S, Baghwagar S, Neumeister V, Pelekanou V, Hatzis C, Pusztai L. Abstract PD6-02: Immunological differences between primary and metastatic breast cancer. Cancer Research 2018, 78: pd6-02-pd6-02. DOI: 10.1158/1538-7445.sabcs17-pd6-02.
• Genetic Evaluation for Women at Increased RiskBrierley K, Healy C, Hofstatter E. Genetic Evaluation for Women at Increased Risk. 2017, 15-30. DOI: 10.1007/978-3-319-59198-8_2.
• Comparison of epigenetic aging in normal breast tissue from women with and without breast cancer.Hofstatter E, Horvath S, Chagpar A, Wali V, Bossuyt V, Storniolo A, Patwardhan G, Von Wahlde M, Pusztai L. Comparison of epigenetic aging in normal breast tissue from women with and without breast cancer. Journal Of Clinical Oncology 2017, 35: 1522-1522. DOI: 10.1200/jco.2017.35.15_suppl.1522.
• Pathologic complete response (pCR) rates after neoadjuvant pertuzumab (P) and trastuzumab (H) administered concomitantly with weekly paclitaxel (T) and 5-fluorouracil/epirubicin/cyclophosphamide (FEC) chemotherapy for clinical stage I-III HER2-positive breast cancer.Foldi J, Mougalian S, Silber A, Lannin D, Killelea B, Chagpar A, Horowitz N, Frederick C, Rispoli L, Abu-Khalaf M, Sabbath K, Sanft T, Fischbach N, Brandt D, Hofstatter E, DiGiovanna M, Pusztai L. Pathologic complete response (pCR) rates after neoadjuvant pertuzumab (P) and trastuzumab (H) administered concomitantly with weekly paclitaxel (T) and 5-fluorouracil/epirubicin/cyclophosphamide (FEC) chemotherapy for clinical stage I-III HER2-positive breast cancer. Journal Of Clinical Oncology 2017, 35: 577-577. DOI: 10.1200/jco.2017.35.15_suppl.577.
• Safety of MEDI4736 (anti-PD-L1 antibody) administered concomitant with weekly nab-paclitaxel and dose dense doxorubicin/cyclophosphamide (ddAC) as neoadjuvant chemotherapy for stage I-III triple negative breast cancer (TNBC): A Phase I/II trial.Pusztai L, Silber A, Hofstatter E, Chung G, Horowitz N, Lannin D, Killelea B, Chagpar A, Szekely B, Frederick C, Rispoli L, DiGiovanna M. Safety of MEDI4736 (anti-PD-L1 antibody) administered concomitant with weekly nab-paclitaxel and dose dense doxorubicin/cyclophosphamide (ddAC) as neoadjuvant chemotherapy for stage I-III triple negative breast cancer (TNBC): A Phase I/II trial. Journal Of Clinical Oncology 2017, 35: 572-572. DOI: 10.1200/jco.2017.35.15_suppl.572.
• Abstract P3-10-01: Investigation of HBOC germline mutations in women diagnosed with breast cancer in Trinidad and TobagoParkinson G, Chagpar A, Hofstatter E, Nunez-Smith M. Abstract P3-10-01: Investigation of HBOC germline mutations in women diagnosed with breast cancer in Trinidad and Tobago. Cancer Research 2017, 77: p3-10-01-p3-10-01. DOI: 10.1158/1538-7445.sabcs16-p3-10-01.
• Management Strategies for Sexual Health After Breast Cancer DiagnosisOverton E, Hofstatter E, Miller D, Ratner E. Management Strategies for Sexual Health After Breast Cancer Diagnosis. 2017, 303-322. DOI: 10.1007/978-3-319-42451-4_19.
• Onset of side effects and adherence to endocrine therapy in the Breast Cancer Endocrine Therapy Adherence (BETA) pilot study.Epstein L, Jhaveri A, Han G, Abu-Khalaf M, Hofstatter E, Sanft T, DiGiovanna M, Silber A, Adelson K, Chung G, Gross C, Pusztai L, Mougalian S. Onset of side effects and adherence to endocrine therapy in the Breast Cancer Endocrine Therapy Adherence (BETA) pilot study. Journal Of Clinical Oncology 2016, 34: e18136-e18136. DOI: 10.1200/jco.2016.34.15_suppl.e18136.
• Defekte homologe Rekombination als einheitlicher Biomarker beim MammakarzinomWahlde M, Timms K, Chagpar A, Wali V, Jiang T, Bossuyt V, Saglam O, Reid J, Gutin A, Neff C, Lanchbury J, Hatzis C, Hofstatter E, Pustzai L. Defekte homologe Rekombination als einheitlicher Biomarker beim Mammakarzinom. Senologie - Zeitschrift Für Mammadiagnostik Und -therapie 2016, 13 DOI: 10.1055/s-0036-1583463.
• Abstract P5-11-03: Development of an interactive text messaging tool to improve adherence with adjuvant endocrine therapy: Breast cancer endocrine therapy adherence (BETA) pilot studyEpstein L, Jhaveri A, Han G, Abu-Khalaf M, Hofstatter E, Sanft T, DiGiovanna M, Silber A, Adelson K, Chung G, Pusztai L, Gross C, Mougalian S. Abstract P5-11-03: Development of an interactive text messaging tool to improve adherence with adjuvant endocrine therapy: Breast cancer endocrine therapy adherence (BETA) pilot study. Cancer Research 2016, 76: p5-11-03-p5-11-03. DOI: 10.1158/1538-7445.sabcs15-p5-11-03.
• Abstract 3879: Patient preferences for disclosure of incidental genetic information discovered through high-throughput sequencingYushak M, Bouberhan S, Han G, Epstein L, Mougalian S, Abu-Khalaf M, Chung G, DiGiovanna M, Sanft T, Pusztai L, Hofstatter E. Abstract 3879: Patient preferences for disclosure of incidental genetic information discovered through high-throughput sequencing. 2015, 3879-3879. DOI: 10.1158/1538-7445.am2015-3879.
• Discovery and disclosure of incidental genetic information obtained through high throughput sequencing.Hofstatter E, Yushak M, Bouberhan S, Han G, Epstein L, Pusztai L. Discovery and disclosure of incidental genetic information obtained through high throughput sequencing. Journal Of Clinical Oncology 2015, 33: e17779-e17779. DOI: 10.1200/jco.2015.33.15_suppl.e17779.
• Reproducibility of homologous recombination deficiency (HRD) scores in biopsies of triple negative breast cancer (TNBC) tumors.Timms K, Chagpar A, Wali V, Bossuyt V, Reid J, Gutin A, Neff C, Hofstatter E, Lanchbury J, Pusztai L. Reproducibility of homologous recombination deficiency (HRD) scores in biopsies of triple negative breast cancer (TNBC) tumors. Journal Of Clinical Oncology 2015, 33: 1091-1091. DOI: 10.1200/jco.2015.33.15_suppl.1091.
• Mutation-based treatment recommendations from next generation sequencing data: A comparison of web tools.Patel J, Reiner E, Bossuyt V, Epstein L, Platt J, DiGiovanna M, Chung G, Silber A, Sanft T, Hofstatter E, Mougalian S, Abu-Khalaf M, Gershkovich P, Hatzis C, Pusztai L. Mutation-based treatment recommendations from next generation sequencing data: A comparison of web tools. Journal Of Clinical Oncology 2015, 33: e12564-e12564. DOI: 10.1200/jco.2015.33.15_suppl.e12564.
• Prospective study of the decision-making impact of the Breast Cancer Index in the selection of patients with ER+ breast cancer for extended endocrine therapy.Sanft T, Aktas B, Schroeder B, Bossuyt V, DiGiovanna M, Abu-Khalaf M, Chung G, Silber A, Hofstatter E, Mougalian S, Epstein L, Hatzis C, Schnabel C, Pusztai L. Prospective study of the decision-making impact of the Breast Cancer Index in the selection of patients with ER+ breast cancer for extended endocrine therapy. Journal Of Clinical Oncology 2015, 33: 538-538. DOI: 10.1200/jco.2015.33.15_suppl.538.
• Abstract P4-12-11: Patient perceptions of the impact of genetic testing for breast cancer risk on health insuranceHofstatter E, Chagpar A. Abstract P4-12-11: Patient perceptions of the impact of genetic testing for breast cancer risk on health insurance. 2015, p4-12-11-p4-12-11. DOI: 10.1158/1538-7445.sabcs14-p4-12-11.
• Abstract P3-07-19: Breast cancer risk perception and adherence to U.S. cancer prevention guidelinesHofstatter E, Chagpar A. Abstract P3-07-19: Breast cancer risk perception and adherence to U.S. cancer prevention guidelines. 2015, p3-07-19-p3-07-19. DOI: 10.1158/1538-7445.sabcs14-p3-07-19.
• Cardiac outcomes in women receiving aromatase inhibitors as adjuvant endocrine therapy for breast cancer.Park E, Abu-Khalaf M, Hatzis C, LaSala J, Silber A, Hofstatter E, Sanft T, Russell R. Cardiac outcomes in women receiving aromatase inhibitors as adjuvant endocrine therapy for breast cancer. Journal Of Clinical Oncology 2014, 32: e11501-e11501. DOI: 10.1200/jco.2014.32.15_suppl.e11501.
• Pilot study of sorafenib and biweekly capecitabine in patients with advanced breast and gastrointestinal tumors.Jhaveri A, Abu-Khalaf M, DiGiovanna M, Pusztai L, Hofstatter E, Sanft T, Sowers N, Lurie B, Silber A, Brandt D, Hochster H, Lacy J, Stein S, Chung G. Pilot study of sorafenib and biweekly capecitabine in patients with advanced breast and gastrointestinal tumors. Journal Of Clinical Oncology 2014, 32: 2561-2561. DOI: 10.1200/jco.2014.32.15_suppl.2561.
• Abstract P5-13-04: What’s your excuse?: Reasons women with a first degree family history of breast cancer don’t get mammogramsHibler L, Hofstatter E, Chagpar A. Abstract P5-13-04: What’s your excuse?: Reasons women with a first degree family history of breast cancer don’t get mammograms. Cancer Research 2013, 73: p5-13-04-p5-13-04. DOI: 10.1158/0008-5472.sabcs13-p5-13-04.
• Abstract P5-13-05: Richer and wiser: Factors correlated with chemoprevention use in the United StatesHofstatter E, Lannin D, Horowitz N, Killelea B, Tsangaris T, Pusztai L, Chung G, Sanft T, DiGiovanna M, AbuKhalaf M, Mougalian S, Chagpar A. Abstract P5-13-05: Richer and wiser: Factors correlated with chemoprevention use in the United States. Cancer Research 2013, 73: p5-13-05-p5-13-05. DOI: 10.1158/0008-5472.sabcs13-p5-13-05.
• Abstract P3-14-02: Patterns of the use of primary systemic therapy in the United StatesMougalian S, Abu-Khalaf M, Sanft T, Hofstatter E, DiGiovanna M, Chung G, Lannin D, Killelea B, Pusztai L, Chagpar A. Abstract P3-14-02: Patterns of the use of primary systemic therapy in the United States. Cancer Research 2013, 73: p3-14-02-p3-14-02. DOI: 10.1158/0008-5472.sabcs13-p3-14-02.
• Abstract P6-06-37: Predicting improvements in survival based on improvements in pathologic response rate to neoadjuvant chemotherapy in different breast cancer subtypesHatzis C, Gould R, Zhang Y, Abu-Khalaf M, Chung G, Sanft T, Hofstatter E, DiGiovanna M, Shi W, Chagpar A, Symmans W, Pusztai L. Abstract P6-06-37: Predicting improvements in survival based on improvements in pathologic response rate to neoadjuvant chemotherapy in different breast cancer subtypes. Cancer Research 2013, 73: p6-06-37-p6-06-37. DOI: 10.1158/0008-5472.sabcs13-p6-06-37.
• Abstract P6-06-09: Baseline assessment of left ventricular function for breast cancer patients undergoing anthracycline and/or trastuzumab: What is the prevalence of baseline dysfunction?Abu-Khalaf M, Medic I, Hatzis C, Park E, Chung G, DiGiovanna M, Hofstatter E, Sanft T, Pusztai L, Gross C, Russell K, Russell R. Abstract P6-06-09: Baseline assessment of left ventricular function for breast cancer patients undergoing anthracycline and/or trastuzumab: What is the prevalence of baseline dysfunction? Cancer Research 2013, 73: p6-06-09-p6-06-09. DOI: 10.1158/0008-5472.sabcs13-p6-06-09.
• Abstract P2-11-22: The use and influence of a 21 gene rearrangement assay in breast cancer: Clinical and pathologic predictors of recurrence score and chemotherapy receiptRutter C, Mancini B, Gross C, Aminawung J, Chagpar A, Saglam O, Hofstatter E, Abu-Khalaf M, Evans S. Abstract P2-11-22: The use and influence of a 21 gene rearrangement assay in breast cancer: Clinical and pathologic predictors of recurrence score and chemotherapy receipt. Cancer Research 2013, 73: p2-11-22-p2-11-22. DOI: 10.1158/0008-5472.sabcs13-p2-11-22.
• Abstract B59: Bilateral oophorectomy at age 55 or older does not reduce risk of breast cancerHofstatter E, Chagpar A. Abstract B59: Bilateral oophorectomy at age 55 or older does not reduce risk of breast cancer. Cancer Prevention Research 2013, 6: b59-b59. DOI: 10.1158/1940-6215.prev-13-b59.
• The impact of survivorship care plans on knowledge among breast cancer survivors.Bulloch K, Irwin M, Chagpar A, Horowitz N, Killelea B, Pusztai L, Abu-Khalaf M, DiGiovanna M, Chung G, Hofstatter E, Levy A, Sanft T. The impact of survivorship care plans on knowledge among breast cancer survivors. Journal Of Clinical Oncology 2013, 31: 124-124. DOI: 10.1200/jco.2013.31.26_suppl.124.
• Phase I study of the HDAC inhibitor vorinostat in combination with capecitabine in a biweekly schedule in advanced breast cancer.James E, Chung G, Sowers N, Clark M, Lilian R, Abraham G, Chmael S, Cappiello M, DiGiovanna M, Hofstatter E, Sanft T, Israel G, Pusztai L, Harris L, Abu-Khalaf M. Phase I study of the HDAC inhibitor vorinostat in combination with capecitabine in a biweekly schedule in advanced breast cancer. Journal Of Clinical Oncology 2013, 31: 154-154. DOI: 10.1200/jco.2013.31.26_suppl.154.
• A pilot chemoprevention study of isopropanolic black cohosh extract in women with ductal carcinoma in situ.Hofstatter E, Stavris K, Horowitz N, Killelea B, Tsangaris T, Lannin D, Andrejeva L, Cong X, Yao X, Rimm D, Chagpar A. A pilot chemoprevention study of isopropanolic black cohosh extract in women with ductal carcinoma in situ. Journal Of Clinical Oncology 2013, 31: tps1609-tps1609. DOI: 10.1200/jco.2013.31.15_suppl.tps1609.
• Rothman index as a predictor for type of discharge and readmission rates in a cancer hospital: The Yale experience.Morgensztern D, Xia B, Kournioti C, Hofstatter E, Raucci M, Keyes A, Morrione A, Blasiak E, Rosenberg E, Rimar J, Rothman M, Lilenbaum R. Rothman index as a predictor for type of discharge and readmission rates in a cancer hospital: The Yale experience. Journal Of Clinical Oncology 2013, 31: 6635-6635. DOI: 10.1200/jco.2013.31.15_suppl.6635.
• Clinical experience with exemestane in postmenopausal women at increased risk of breast cancer.Sorkin M, Lapolt D, Pusztai L, Hofstatter E. Clinical experience with exemestane in postmenopausal women at increased risk of breast cancer. Journal Of Clinical Oncology 2013, 31: 1565-1565. DOI: 10.1200/jco.2013.31.15_suppl.1565.
• Phase I study of the HDAC inhibitor vorinostat in combination with capecitabine in a biweekly schedule in advanced breast cancer.James E, Chung G, DiGiovanna M, Sanft T, Hofstatter E, Sowers N, Clark M, Lilian R, Chmael S, Cappiello M, Abraham G, Israel G, Pusztai L, Harris L, Abu-Khalaf M. Phase I study of the HDAC inhibitor vorinostat in combination with capecitabine in a biweekly schedule in advanced breast cancer. Journal Of Clinical Oncology 2013, 31: 2587-2587. DOI: 10.1200/jco.2013.31.15_suppl.2587.
• State of the Art in Imaging and Chemoprevention for High-Risk PatientsHofstatter E, Andrejeva L, Chagpar A. State of the Art in Imaging and Chemoprevention for High-Risk Patients. Current Breast Cancer Reports 2013, 5: 125-133. DOI: 10.1007/s12609-013-0104-1.
• Understanding patients’ attitudes toward communication about the cost of cancer care.Bullock A, Hofstatter E, Yushak M, Buss M. Understanding patients’ attitudes toward communication about the cost of cancer care. Journal Of Clinical Oncology 2011, 29: 6065-6065. DOI: 10.1200/jco.2011.29.15_suppl.6065.